


Trimethylguanosine Cap-Fluorescent Molecular Rotor conjugates (TMG-FMR) are potent, specific snurportin1 ligands enabling visualization in living cells

Piotr Surynt^{a, b}, Blazej A. Wojtczak^b, Mikolaj Chrominski^b, Joanna Panecka-Hofman^b, Karina Kwapiszewska^c, Tomasz Kalwarczyk^c, Dorota Kubacka^a, Tomasz Spiewla^a, Renata Kasprzyk^b, Robert Holyst^c, Joanna Kowalska^a, Jacek Jemielity^{*,b}


^a Division of Biophysics, Faculty of Physics, University of Warsaw, Pasteura 5, 02-093, Warsaw, Poland

^b Centre of New Technologies, University of Warsaw, Banacha 2c, 02-097, Warsaw, Poland


^c Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224, Warsaw, Poland



Scheme S1. General CuAAC schemes and structures of different obtained GMP with linkers (azide/alkyne group) and conjugates with FMR



Scheme S2. Synthesis of functionalized GMP CuAAC reagents **10-** and **11-2'/3'** and FMR conjugates **12a-d**. Compounds **20-25** are FMR derivatives, CuAAC reagents



Scheme S3. Synthesis of FMR derivatives **20-25**




Figure S1. Exemplary FQT curves for TMG cap with linkers either from G or TMG side.




Figure S2. Exemplary FQT curves for complexes of snurportin1 and 2'-O- (top) or 3'-O-substituted (bottom) TMGpppG conjugates with different FMRs, TMGpppG (gray) was a standard.




Figure S3. Dissociation constants (K_D) for complexes of snurportin1 and different GMP-FMR conjugates (**10**, **11**) and FMR-CH₂-triazole-CH₂-phosphonates (**12**, **a-c**)




Figure S4: Interaction diagram for the unsubstituted TMGpppG in the snurportin1 binding site with exclusion of water-mediated interactions.




Figure S5. Dual emission for unbound **1a-2'** originating from phenol and phenolate DMHBI forms excited at A. 390 nm, B. 490 nm.





Figure S6. Comparison of dissociation constants and probes responses (F_{max}/F_0) for all A. DMHBI conjugates, B. oHBI conjugates





Figure S7. Comparison of dissociation constants and probes responses (F_{max}/F_0) for all A. HEMABI conjugates, B. ACVJ conjugates





Figure S8. Initial (F0) and partly or fully saturated with snurportin1 (Fmax) normalized to concentration fluorescence intensities, A. DMHBI conjugatesl B. oHBI conjugates





Figure S9. Initial (F0) and partly or fully saturated with snurportin1 (Fmax) normalized to concentration fluorescence intensities. A. HEMABI conjugates. B. ACVJ conjugates




Figure S10. Representative merged emission spectra (excited at 390 nm) for DMHBI conjugates titrated with snurportin, binding curves for ligands titrations with snurportin and FQT curves (titrations with ligand)




Figure S11. Representative merged emission spectra (excited at 490 nm) for DMHBI conjugates titrated with snurportin, binding curves for titrations with snurportin and FQT curves (titrations with ligand)




Figure S12. Representative merged emission spectra for oHBI conjugates titrated with snurportin, binding curves for ligands titrations with snurportin and FQT curves (titrations with ligand)





Figure S13. Representative merged emission spectra for HEMABI conjugates titrated with snurportin, binding curves for ligands titrations with snurportin and FQT curves (titrations with ligand)




Figure S14. Merged emission spectra for all tested ACVJ conjugates titrated with snurportin binding curves for ligands titrations with snurportin and FQT curves.




Figure S15. The histograms of the fluorescence lifetimes extracted from the FLIM images depicted in Figure 9.

Table S1. Spectral properties of Fluorescent Molecular Rotors monophosphates derivatives

FMR derivative	$\lambda_{\text{abs}}^{\text{a}}$	$\lambda_{\text{em}}^{\text{b}}$	Stokes Shift (nm)
DMHBI-CH₂-triazole-CH₂-phosphate (12a)	390 / 490	490 / 525	100 / 35
oHBI-CH₂-triazole-CH₂-phosphate (12b)	390	605	215
HEMABI-CH₂-triazole-CH₂-phosphate (12c)	455	535	80
ACVJ-CH₂-triazole-CH₂-phosphate (12d)	465	535	70

^a – in KH₂PO₄ buffer pH 7 ; ^b – in HEPES buffer pH 7.2**Table S2.** Determined K_D for different TMG capped ligands and non TMG-cap-FMR conjugates with snurportin1 based on FQT experiments and fluorescence enhancement values (F_m/F₀) based on saturation experiments paired with maximum emission wavelengths

Compound	K _D (nM)	Compound	K _D (nM)	F _m /F ₀ (λ_{exc_1})	λ_{em_1} for F _m (nm)	F _m /F ₀ (λ_{exc_2})	λ_{em_2} for F _m (nm)
TMGpppG	1111 ± 74	10a-2'	159.3 ± 5.6	23.1	549	10.4	545
TMGppCH₂pG	1316 ± 17 ^a	10a-3'	NA	1.2	531	2.1	548
TMGpCH₂ppG	2564 ± 656 ^a	10b-2'	105 ± 11	6.4	583	-	-
TMGpppA	5263 ± 277 ^a	10b-3'	>10000	3.1	609	-	-
TMGpppG	417 ± 6.9 ^a	10c-2'	182 ± 12	7.4	531	-	-
1-2'	1113 ± 77	10c-3'	1007 ± 46	2.4	527	-	-
1-3'	876 ± 73	10d-2'	>20000	2.4	514	-	-
2-2'	148 ± 12	10d-3'	ND	1.1	512	-	-
2-3'	257 ± 21	11b-2'	>10000	1.1	585	-	-
3-2'	681 ± 32	11b-3'	>10000	1.2	586	-	-
3-3'	780 ± 138	12a	>10000	ND	ND	ND	ND
4-2'	1287 ± 232	12b	>10000	ND	ND	-	-
4-3'	5882 ± 3806	12c	9434 ± 1513	1.0	525	-	-
5-2'	154 ± 5.6	12d	ND	ND	ND	-	-
5-3'	272 ± 18						
6-2'	155 ± 23						
6-3'	343 ± 20						
7-2'	548 ± 129						
7-3'	609 ± 19						
8	No binding						
9-2'	>10000						
9-3'	893 ± 167						

^a M. Waszczuk, Ph.D Thesis, 2017

NA – not applicable, ND – not determined

Table S3. Top 10 poses of 2'-o-HBI in **1b-2'** and 3'-o-HBI in **1b-3'** ranked by docking score, and ligand strain energies (E_strain).

2'-o-HBI (1b-2')			3'-o-HBI (1b-3')		
pose no.	docking score [kcal/mol]	E_strain [kcal/mol]	pose no.	docking score [kcal/mol]	E_strain [kcal/mol]
1	-4.39	11.07	1	-4.11	15.38
2	-4.39	9.14	2	-3.88	17.32
3	-4.07	21.21	3	-3.88	10.37
4	-4.05	10.28	4	-3.87	15.93
5	-4.04	20.61	5	-3.83	11.73
6	-3.99	11.13	6	-3.82	13.55
7	-3.98	15.31	7	-3.8	7.07
8	-3.93	11.68	8	-3.78	14.33
9	-3.84	11.93	9	-3.77	13.22
10	-3.62	23.05	10	-3.71	14.14

DMHBI-methyl-1H-1,2,3-triazol-1-yl)methyl monophosphonate (12a)

Obtained according to GP C starting from 300 µL (8.16 mg, 60 µmol) of **12** (200 mM H₂O solution), 300 µL (9.00 mg, 30 µmol) of **20** (100 mM DMSO solution), 3.56 mg (6 µmol, 60 µL of 100 mM H₂O/DMSO solution) of CuSO₄-THPTA, 2.38 mg (12 µmol, 120 µL of 100 mM H₂O solution) of sodium ascorbate. The reaction was quenched by adding 2.23 mg (6 µmol, 60 µL of 100 mM H₂O solution) of Na₂EDTA. The RP HPLC (Kinetex C8 column) purification afforded 19.93 mg of **12a** ammonium salt (Yield = 76%). Rt = 14.46 min
HRMS (ESI) m/z, 436.1028 calculated for C₁₇H₁₉N₅O₇P⁻ ; found 436.1029

o-HBI-methyl-1H-1,2,3-triazol-1-yl)methyl monophosphonate (12b)

Obtained according to GP C starting from 300 µL (8.16 mg, 60 µmol) of **12** (200 mM H₂O solution), 300 µL (7.20 mg, 30 µmol) of **21** (100 mM DMSO solution), 3.56 mg (6 µmol, 60 µL of 100 mM H₂O/DMSO solution) of CuSO₄-THPTA, 2.38 mg (0.012 µmol, 120 µL of 100 mM H₂O solution) of sodium ascorbate. The reaction was quenched by adding 2.23 mg (6 µmol, 60 µL of 100 mM H₂O solution) of Na₂EDTA. The RP HPLC (Kinetex C8 column) purification afforded 16.74 mg of **12b** ammonium salt (Yield = 74%). Rt = 16.39 min
HRMS (ESI) m/z, 376.0816 calculated for C₁₅H₁₅N₅O₅P⁻ ; found 376.0820

HEMABI-methyl-1H-1,2,3-triazol-1-yl)methyl monophosphonate (12c)

Obtained according to GP C starting from 300 µL (8.16 mg, 60 µmol) of **12** (200 mM H₂O solution), 300 µL (8.91 mg, 30 µmol) of **22** (100 mM DMSO solution), 3.56 mg (6 µmol, 60 µL of 100 mM H₂O/DMSO solution) of CuSO₄-THPTA, 2.38 mg (12 µmol, 120 µL of 100 mM H₂O solution) of sodium ascorbate. The reaction was quenched by adding 2.23 mg (6 µmol, 60 µL of 100 mM H₂O solution) of Na₂EDTA. The RP HPLC (Kinetex C8 column) purification afforded 17.98 mg of **12c** ammonium salt (Yield = 69%). Rt = 14.72 min
HRMS (ESI) m/z, 433.1395 calculated for C₁₈H₂₂N₆O₅P⁻ ; found 433.1396

ACVJ-methyl-1H-1,2,3-triazol-1-yl)methyl monophosphonate (12d)

Obtained according to GP C starting from 300 µL (8.16 mg, 60 µmol) of **12** (200 mM H₂O solution), 300 µL (9.16 mg, 30 µmol) of **23** (100 mM DMSO solution), 3.56 mg (6 µmol, 60 µL

of 100 mM H₂O/DMSO solution) of CuSO₄-THPTA, 2.38 mg (12 µmol, 120 µL of 100 mM H₂O solution) of sodium ascorbate. The reaction was quenched by adding 2.23 mg (6 µmol, 60 µL of 100 mM H₂O solution) of Na₂EDTA. The RP HPLC (Kinetex C8 column) purification afforded 16.98 mg of **12d** ammonium salt (Yield = 64%). Rt = 21.42 min (gradient c)
HRMS (ESI) m/z, 441.1446 calculated for C₂₀H₂₂N₆O₄P⁻; found 441.1450

2'+3'-O-(N-(2-Azidoethyl)carbamoyl) guanosine 5'-diphosphate imidazolide (13)

Obtained according to GP A: GDP triethylammonium salt (98 mg, 0.10 mmol, 1200 mOD) was dissolved in DMSO (2 ml) and CDI (97 mg, 0.600 mmol, 6 equiv) was added. The mixture was stirred and microwaved as described in GP A, then excess of CDI was hydrolyzed by addition of H₂O (22 µL) and after 15 min of stirring, 2-azidoethylamine (54 µL, 0.60 mmol, 6 equiv) and DBU (15 µL, 0.10 mmol, 1 equiv) was added. The reaction mixture was stirred at RT and monitored by HPLC. After 6h the imidazolide was precipitated by addition of NaClO₄ (73 mg, 0.60 mmol, 6 equiv) in 40 ml cold acetone. 26 mg of imidazolide sodium salt was obtained as a mixture of 2' and 3' isomers. (611 mOD, Yield = 51%). Rt = min

HRMS (ESI) m/z, 604.0825 calculated for C₁₆H₂₀N₁₁O₁₁P₂⁻; found 604.0831

2'+3'-O-(N-(2-Azidoethyl)carbamoyl)guanosine 5'-methylene(bisphosphonate) imidazolide (14)

Obtained according to GP A: GpCH₂p triethylammonium salt (98 mg, 0.10 mmol, 1200 mOD) was dissolved in DMSO (2 ml) and CDI (97 mg, 0.600 mmol, 6 equiv) was added. The mixture was stirred and microwaved as described in GP A, then excess of CDI was hydrolyzed by addition of H₂O (22 µL) and after 15 min of stirring, 2-azidoethylamine (54 µL, 0.60 mmol, 6 equiv) and DBU (15 µL, 0.10 mmol, 1 equiv) was added. The reaction mixture was stirred at RT and monitored by HPLC. After 6h the imidazolide was precipitated by addition of NaClO₄ (73 mg, 0.60 mmol, 6 equiv) in 40 ml cold acetone. 40 mg of Imidazolide sodium salt was obtained as a mixture of 2' and 3' isomers based on chromatogram, however, due to aqueous environment, imidazolide hydrolyzed to phosphonate before HRMS analysis. (960 mOD, Yield = 80%). Rt = 6.39 min

HRMS (ESI) m/z, 552.0763 calculated for C₁₄H₂₀N₉O₁₁P₂⁻; found 552.0769

2'+3'-O-(N-(2-Azidoethyl)carbamoyl)adenosine 5'-diphosphate imidazolide (15)

Obtained according to GP A: ADP triethylammonium salt (200 mg, 0.274 mmol) was dissolved in DMSO (5 ml) and CDI (222 mg, 1.37 mmol, 5 equiv) was added. The mixture was stirred at RT for 1h, then excess of CDI was hydrolyzed by addition of H₂O (49 µL) and after 15 min of stirring, 2-azidoethylamine was added (246 µL, 236 mg, 2.73 mmol, 10 equiv). The reaction mixture was stirred at RT and monitored by HPLC. After 24h the imidazolide was precipitated by addition of NaClO₄ (335 mg, 2.73 mmol, 10 equiv) in 50 ml cold acetone. Imidazolide sodium salt was obtained as a mixture of 2' and 3' isomers. (Yield: 91 mg, 52%). Rt = 7.32 min (isomer 2') and 7.93 min (isomer 3')

HRMS (ESI) m/z, 588.0875 calculated for C₁₆H₂₀N₁₁O₁₀P₂⁻; found 588.0881

2'+3'-O-(N-(Propargyl)carbamoyl)guanosine 5'-iodide (16)

5'-I-Guanosine (500 mg, 1.28 mmol) was dissolved in DMSO (20 ml) and CDI (1.03 g, 6.38 mmol, 5 equiv) was added. The mixture was stirred at RT for 1 h, then excess of CDI was hydrolyzed by addition of H₂O (230 µL) and after 15 min of stirring propargylamine was added (702 mg, 12.75 mmol, 10 equiv). The reaction mixture was stirred at RT and monitored by HPLC. After 24 h the crude product was precipitated by addition of 200 ml 1:1 mixture of CH₂Cl₂/H₂O. White precipitate was washed with CH₂Cl₂ and dried in under high vacuum (Yield: 548 mg,

90% as a mixture of 2' and 3' isomers). Rt = 15.58 min (isomer 3') and 16.45 min (isomer 2'). For NMR analysis small amount of isomers were separated and purified on RP-HPLC.

Isomer 2' (Rt = 16.45 min)

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 7.91 (d, J = 4.9 Hz, 1H), 7.86 (s, 1H), 6.27 (s, 1H), 5.15 (d, J = 14.9 Hz, 1H), 4.92 (dd, J = 5.6, 3.4 Hz, 1H), 4.79 (d, J = 3.3 Hz, 1H), 4.11 (d, J = 5.7 Hz, 1H), 3.78 – 3.74 (m, 2H)

Isomer 3' (Rt = 15.58 min)

¹H NMR (500 MHz, DMSO-d₆) δ [ppm] 7.93 (s, 1H), 5.70 (d, J = 7.6 Hz, 1H), 5.12 (dd, J = 5.4, 2.1 Hz, 1H), 4.93 (dd, J = 7.5, 5.4 Hz, 1H), 4.11 (td, J = 6.7, 2.2 Hz, 1H), 3.76 (d, J = 5.6 Hz, 1H).

HRMS (ESI) m/z, 473.0076 calculated for C₁₄H₁₄IN₆O₅⁻ ; found 473.0080

2'+3'-O-(N-(Propargyl)carbamoyl)guanosine 5'-monothiophosphate (17)

To a suspension of 2'+3'-O-(N-(Propargyl)carbamoyl)guanosine 5'-iodide (**16**) (0.5 g, 1.06 mmol) in 10 mL of DMF, trisodium thiophosphate (0.53 g, 1.27 mmol) was added followed by addition of Et₃N (0.43 g, 728 µL, 4.23 mmol). The reaction mixture was stirred for 6 h at 5°C. The reaction mixture was dissolved in 50 mL of water and purified by AIEC on Sephadex. The fractions containing the desired product were collected and freeze-dried. Yield: 6186 mOD, 0.51 mmol (Yield = 64%). Rt = 6.44 min

¹H NMR (500 MHz, DMSO-*d*₆) δ [ppm] 7.99 (s, 1H), 7.96 (s, 1H), 5.91 (d, *J* = 6.2 Hz, 1H), 5.81 (d, *J* = 3.8 Hz, 1H), 5.68 (d, *J* = 7.5 Hz, 1H), 5.63 (d, *J* = 7.6 Hz, 1H), 5.48 (t, *J* = 5.8 Hz, 1H), 5.35 (dd, *J* = 5.6, 3.7 Hz, 1H), 5.24 (d, *J* = 5.2 Hz, 1H), 5.13 (dd, *J* = 5.4, 2.2 Hz, 1H), 5.03 (dd, *J* = 7.7, 5.0 Hz, 1H), 4.87 (dd, *J* = 7.6, 5.5 Hz, 1H), 4.75 (t, *J* = 5.8 Hz, 1H), 4.40 (dd, *J* = 5.3, 3.6 Hz, 1H), 4.19 (d, *J* = 7.4 Hz, 1H), 4.05 (td, *J* = 6.2, 2.1 Hz, 1H), 3.93 (td, *J* = 6.1, 3.6 Hz, 1H), 3.13 (d, *J* = 2.5 Hz, 1H), 3.09 (d, *J* = 2.4 Hz, 1H)

³¹P NMR (203 MHz, DMSO-*d*₆) δ [ppm] 12.09 (s, 1P), 11.72 (s, 1P)

HRMS (ESI) m/z, 459.0493 calculated for C₁₄H₁₆N₆O₈PS⁻ ; found 459.0501

2'+3'-O-(N-(Propargyl)carbamoyl)guanosine 5'-monothiophosphate imidazolide (18)

Compound **18** was prepared according to Mukaiyama protocol ^{1,2}. 2'+3'-O-(N-(Propargyl)-carbamoyl)guanosine 5'-monothiophosphate (**17**) (TEA+ salt, 1 g, 1.51 mmol), imidazole (1.03 g, 15.09 mmol, 10 equiv), 2,2'-dithiodipyridine (DTDP) (997.25 mg, 4.53 mmol, 3 equiv) were mixed in DMF (10 mL) before addition of triethylamine (458.06 mg, 4.53 mmol, 3 equiv) and triphenylphosphine (PPh₃) (1.19 g, 4.53 mmol, 3 equiv). The mixture was stirred for 6 h or overnight at room temperature and progress was monitored by HPLC. Addition of a solution of anhydrous NaClO₄ (1.84 g) in 100 mL dry acetone resulted in precipitation of the product as sodium salt. The suspension was cooled at 4 °C and the precipitate was filtered off, washed repeatedly with cold, dry acetone and dried in vacuum over P₄O₁₀. (Yield: 914 mg, 87%). Rt = 9.65 min (isomer 2') and 10.58 min (isomer 3')

HRMS (ESI) m/z, 509.0762 calculated for C₁₇H₁₈N₈O₇PS⁻ ; found 509.0764

2'+3'-O-(N-(2-Azidoethyl)carbamoyl)-2,2,7-trimethylguanosine monophosphate imidazolide (19)

Obtained according to GP A: TMGMP triethylammonium salt (25 mg, 0.052 mmol, 622 mOD) was dissolved in DMSO (1 ml) and CDI (51 mg, 0.310 mmol, 6 eqiv) was added. The mixture was stirred and microwaved as described in GP A, then excess of CDI was hydrolyzed by addition of H₂O (14 µL) and after 15 min of stirring, 2-azidoethylamine (20 µL, 0.310 mmol, 6 eqiv) and DBU (20 µL, 0.052 mmol, 1 eqiv) was added. The reaction mixture was stirred at RT and monitored by HPLC. After 6h the imidazolide was precipitated by addition of LiClO₄ (33 mg, 0.310 mmol, 6 eqiv) in 40 ml cold acetonitrile. Imidazolide lithium salt was obtained as a mixture of 2' and 3' isomers. (Yield: 19 mg, 387 mOD, 62%).

HRMS (ESI) m/z, 566.1631 calculated for C₁₉H₂₅N₁₁O₈P⁻ ; found 566.1633

References

1. T. Mukaiyama and M. Hashimoto, *J. Am. Chem. Soc.*, 1972, **94** (24), 8528–8532.
2. T. Mukaiyama and M. Hashimoto, *Bulletin of the Chemical Society of Japan*, 1971, **44** (8), 2284.

TABLE OF CONTENTS

Compound 1-2': TMG _n pppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -N ₃ (NH ₄ ⁺ salt)	25
Compound 1-3': TMG _n pppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -N ₃ (NH ₄ ⁺ salt).....	30
Compound 2-2': TMG-5'-S-pppG-2'-O-C(O)NH-CH ₂ CH ₂ N ₃ (NH ₄ ⁺ salt)	37
Compound 2-3': TMG-5'-S-pppG-3'-O-C(O)NH-CH ₂ CH ₂ N ₃ (NH ₄ ⁺ salt)	43
Compound 3-2': TMG _n pG-2'-O-C(O)NH-CH ₂ CH ₂ N ₃ (NH ₄ ⁺ salt).....	50
Compound 3-3': TMG _n pG-3'-O-C(O)NH-CH ₂ CH ₂ N ₃ (NH ₄ ⁺ salt).....	55
Compound 4-2': TMG _n pppA-2'-O-C(O)-NH-CH ₂ -CH ₂ -N ₃ (NH ₄ ⁺ salt)	60
Compound 4-3': TMG _n pppA-3'-O-C(O)-NH-CH ₂ -CH ₂ -N ₃ (NH ₄ ⁺ salt)	65
Compound 5-2': TMG _n pppG-2'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	70
Compound 5-3': TMG _n pppG-3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	75
Compound 6: TMG _n pppA-2'+3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	80
Compound 7-2': TMG _n ppp-5'-SG-2'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt)	85
Compound 7-3': TMG _n ppp-5'-SG-3'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt)	91
Compound 8: TMG _n pppG-N1-C ₃ H ₃ (NH ₄ ⁺ salt)	98
Compound 9-2': TMG(-2'-O-C(O)-NH-CH ₂ CH ₂ -N ₃)pppG (NH ₄ ⁺ salt).....	103
Compound 9-3': TMG(-3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃)pppG (NH ₄ ⁺ salt).....	108
Compound 10-2': GMP-2'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	113
Compound 10-3': GMP-3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	120
Compound 11-2': GMP-2'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt)	127
Compound 11-3': GMP-3'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt)	134
Compound 1a-2': TMG _n pppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	141


Compound 1a-3': TMGpppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	143
Compound 1b-2': TMGpppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI (NH ₄ ⁺ salt)	145
Compound 1b-3': TMGpppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI (NH ₄ ⁺ salt)	147
Compound 1c-2': TMGpppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	149
Compound 1c-3': TMGpppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	151
Compound 1d-2': TMGpppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -ACVJ (NH ₄ ⁺ salt)	153
Compound 1d-3': TMGpppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -ACVJ (NH ₄ ⁺ salt)	155
Compound 2a-2': TMG-5'-SpppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	157
Compound 2a-3': TMG-5'-SpppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	159
Compound 3a-2': TMGppCH ₂ pG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	161
Compound 3a-3': TMGppCH ₂ pG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	163
Compound 3c-2': TMGppCH ₂ pG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	165
Compound 3c-3': TMGppCH ₂ pG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	167
Compound 4a-2': TMGpppA-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	169
Compound 4a-3': TMGpppA-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	171
Compound 4c-2': TMGpppA-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	173
Compound 4c-3': TMGpppA-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	175
Compound 5a-2': TMGppppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	177
Compound 5a-3': TMGppppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	179
Compound 5c-2': TMGppppG-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	181
Compound 5c-3': TMGppppG-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	183
Compound 6a: TMGppppA-2'+3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	185
Compound 6c: TMGppppA-2'+3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	187
Compound 7a-2': TMGppp-5'-SG-2'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -DMHBI (NH ₄ ⁺ salt)	189


Compound 7a-3': TMGppp-5'-SG-3'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -DMHBI (NH ₄ ⁺ salt)	191
Compound 7b-2': TMGppp-5'-SG-2'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -oHBI (NH ₄ ⁺ salt)	193
Compound 7b-3': TMGppp-5'-SG-3'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -oHBI (NH ₄ ⁺ salt)	195
Compound 8a: TMGpppG-N1-CH ₂ -triazole-CH ₂ CH ₂ -DMHBI (NH ₄ ⁺ salt).....	197
Compound 8b: TMGpppG-N1-CH ₂ -triazole-CH ₂ CH ₂ -oHBI (NH ₄ ⁺ salt).....	199
Compound 9a-2': TMG(-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI)pppG (NH ₄ ⁺ salt)	201
Compound 9a-3': TMG(-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI)pppG (NH ₄ ⁺ salt)	203
Compound 9b-2': TMG(-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI)pppG (NH ₄ ⁺ salt).....	205
Compound 9b-3': TMG(-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI)pppG (NH ₄ ⁺ salt).....	207
Compound 10a-2': GMP-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	209
Compound 10a-3': GMP-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	211
Compound 10b-2': GMP-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI (NH ₄ ⁺ salt)	213
Compound 10b-3': GMP-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -oHBI (NH ₄ ⁺ salt)	215
Compound 10c-2': GMP-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	217
Compound 10c-3': GMP-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt)	219
Compound 10d-2': GMP-2'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -ACVJ (NH ₄ ⁺ salt)	221
Compound 10d-3': GMP-3'-O-C(O)-NH-CH ₂ -CH ₂ -triazole-CH ₂ -ACVJ (NH ₄ ⁺ salt)	223
Compound 11b-2': GMP-2'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -oHBI (NH ₄ ⁺ salt)	225
Compound 11b-3': GMP-3'-O-C(O)-NH-CH ₂ -triazole-CH ₂ CH ₂ -oHBI (NH ₄ ⁺ salt)	227
Compound 12a: phosphonate-CH ₂ -triazole-CH ₂ -DMHBI (NH ₄ ⁺ salt)	229
Compound 12b: phosphonate-CH ₂ -triazole-CH ₂ -oHBI (NH ₄ ⁺ salt).....	231
Compound 12c: phosphonate-CH ₂ -triazole-CH ₂ -HEMABI (NH ₄ ⁺ salt).....	233
Compound 12d: phosphonate-CH ₂ -triazole-CH ₂ -ACVJ (NH ₄ ⁺ salt)	235
Compound 13: Im-GDP-2'+3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	237


Compound 14: Im-GpCH ₂ p-2'+3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	239
Compound 15: Im-ADP-2'+3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt)	241
Compound 16: 5'-I-Guo-2'+3'-O-C(O)-NH-C ₃ H ₃	243
Compound 17: 5'-S-GMP-2'+3'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt).....	245
Compound 18: Im-5'-S-GMP-2'+3'-O-C(O)-NH-C ₃ H ₃ (NH ₄ ⁺ salt)	247
Compound 19: Im-TMGMP-2'+3'-O-C(O)-NH-CH ₂ CH ₂ -N ₃ (NH ₄ ⁺ salt).....	249
Compound 20: DMHBI-C ₃ H ₃	251
Compound 21: oHBI-C ₃ H ₃	255
Compound 22: HEMABI-C ₃ H ₃	261
Compound 23: ACVJ-C ₃ H ₃	265
Compound 24: DMHBI-CH ₂ CH ₂ -N ₃	269
Compound 25: oHBI-CH ₂ CH ₂ -N ₃	273


Compound 1-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2019-12-0617-24-483A_2P_PROFIL.D)</p> <p>mAU</p> <p>300 250 200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>9.140</p>












Compound 1-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-N₃ (NH₄⁺ salt)


Chemical structure											
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2019-12-0908-34-563A_3P_PROFIL.D)</p> <table border="1"><caption>Estimated HPLC Peak Data</caption><thead><tr><th>Time (min)</th><th>Absorbance (mAU)</th></tr></thead><tbody><tr><td>0 - 9.0</td><td>~10</td></tr><tr><td>9.138</td><td>800</td></tr><tr><td>9.2 - 10.0</td><td>~10</td></tr><tr><td>10.5 - 14.0</td><td>~10</td></tr></tbody></table>	Time (min)	Absorbance (mAU)	0 - 9.0	~10	9.138	800	9.2 - 10.0	~10	10.5 - 14.0	~10
Time (min)	Absorbance (mAU)										
0 - 9.0	~10										
9.138	800										
9.2 - 10.0	~10										
10.5 - 14.0	~10										










¹³C NMR (400 MHz, D₂O, 25°C)











Compound 2-2': TMG-5'-S-pppG-2'-O-C(O)NH-CH₂CH₂N₃ (NH₄⁺ salt)

















Compound 2-3': TMG-5'-S-pppG-3'-O-C(O)NH-CH₂CH₂N₃ (NH₄⁺ salt)


Chemical structure




RP-HPLC (conditions c)












¹³C NMR (500 MHz, D₂O, 25°C)










Compound 3-2': TMGppCH₂pG-2'-O-C(O)NH-CH₂CH₂N₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>VWD1 A, Wavelength=254 nm (PIOTRS\2A_2P ISOMER 2019-12-04 12-26-26.D)</p> <p>mAU</p> <p>500 400 300 200 100 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>9.354</p>

MS (-) ESI (Calc. [M-H]⁻ C₂₇H₃₈N₁₄O₁₈P₃⁻ : 939.1707, found: 939.17242)













Compound 3-3': TMGppCH₂pG-3'-O-C(O)NH-CH₂CH₂N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>VWD1 A, Wavelength=254 nm (PIOTRS\2A_3P ISOMER 2019-12-04 19-22-56.D)</p> <p>mAU</p> <p>600 500 400 300 200 100 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>9.368</p>















Compound 4-2': TMGpppA-2'-O-C(O)-NH-CH₂-CH₂-N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (PIOTRS\TMGP3A-L-N30495.D)</p>  <p>mAU</p> <p>4000 3500 3000 2500 2000 1500 1000 500 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>9.147</p>













Compound 4-3': TMGpppA-3'-O-C(O)-NH-CH₂-CH₂-N₃ (NH₄⁺ salt)

Chemical structure									
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\TMGP3A-L-N30497.D)</p> <table border="1"><caption>Estimated peak data from RP-HPLC chromatogram</caption><thead><tr><th>Retention Time (min)</th><th>Absorbance (mAU)</th></tr></thead><tbody><tr><td>9.200</td><td>~400</td></tr><tr><td>9.688</td><td>~200</td></tr><tr><td>9.7</td><td>~2500</td></tr></tbody></table>	Retention Time (min)	Absorbance (mAU)	9.200	~400	9.688	~200	9.7	~2500
Retention Time (min)	Absorbance (mAU)								
9.200	~400								
9.688	~200								
9.7	~2500								















Compound 5-2': TMGpppG-2'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\TMGP4G-L-N30448.D)</p> 













Compound 5-3': TMGpppG-3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\TMGP4G-L-N30449.D)</p> <p>mAU</p> <p>300 250 200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>8.032</p> <p>8.363</p>














Compound 6: TMGpppA-2'+3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)















Compound 7-2': TMGppp-5'-SG-2'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)


Chemical structure									
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\TMGKAP001192.D)</p> <table border="1"><caption>Estimated HPLC Data</caption><thead><tr><th>Time (min)</th><th>Intensity (mAU)</th></tr></thead><tbody><tr><td>0.0 - 8.0</td><td>~10</td></tr><tr><td>8.552</td><td>~850</td></tr><tr><td>10.0 - 15.0</td><td>~10</td></tr></tbody></table>	Time (min)	Intensity (mAU)	0.0 - 8.0	~10	8.552	~850	10.0 - 15.0	~10
Time (min)	Intensity (mAU)								
0.0 - 8.0	~10								
8.552	~850								
10.0 - 15.0	~10								














Compound 7-3': TMGppp-5'-SG-3'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\TMGKAP001191.D)</p> <p>mAU</p> <p>1500 1250 1000 750 500 250 0</p> <p>0 5 10 15 min</p> <p>8.125</p>











¹³C NMR (500 MHz, D₂O, 25°C)











Compound 8: TMG_nG-N1-C₃H₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\GPPPG000685.D)</p> 













Compound 9-2': TMG(-2'-O-C(O)-NH-CH₂CH₂-N₃)pppG (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\TMGKAP000607.D)</p> <p>mAU</p> <p>300 250 200 150 100 50 0</p> <p>0 2.5 5 7.5 10 12.5 min</p> <p>9.288</p>













Compound 9-3': TMG(-3'-O-C(O)-NH-CH₂CH₂-N₃)pppG (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\TMGKAP000604.D)</p> <p>mAU</p> <p>400 300 200 100 0</p> <p>0 2.5 5 7.5 10 12.5 min</p> <p>8.895</p>















Compound 10-2': GMP-2'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\GMP001674.D)</p>  <p>mAU</p> <p>600 500 400 300 200 100 0</p> <p>0 2 4 6 8 10 12 min</p> <p>7.908</p>




















Compound 10-3': GMP-3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\GMP001675.D)</p> 




















Compound 11-2': GMP-2'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (BLAZEJ\GMP001686.D)</p>  <p>mAU</p> <p>175 150 125 100 75 50 25 0</p> <p>0 2 4 6 8 10 12 min</p> <p>7.265</p>


















Compound 11-3': GMP-3'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (BLAZEJ\GMP001685.D)</p> <p>mAU</p> <p>200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 min</p> <p>7.998</p>


















Compound 1a-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)




MS (-) ESI (Calc. [M-H]⁻ C₄₂H₅₂N₁₆O₂₃P₃⁻ : 1241.2610, found: 1241.26563)






Compound 1a-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	





Compound 1b-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions b)	




Compound 1b-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-oHBI (NH₄⁺ salt)







Compound 1c-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	





Compound 1c-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)







Compound 1d-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-ACVJ (NH₄⁺ salt)






Compound 1d-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-ACVJ (NH₄⁺ salt)






Compound 2a-2': TMG-5'-SpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	




Compound 2a-3': TMG-5'-SpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (PIOTRS\2021-01-2211-34-45TMGSPPPG-3P-O-LINKER-DMHBI.D)</p> <p>mAU</p> <p>350 300 250 200 150 100 50 0</p> <p>0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 min</p> <p>DAD1 B, Sig=390.4 Ref=360,100 (PIOTRS\2021-01-2211-34-45TMGSPPPG-3P-O-LINKER-DMHBI.D)</p> <p>mAU</p> <p>250 200 150 100 50</p> <p>0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 min</p>






Compound 3a-2': TMGppCH₂pG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (PIOTRS\2020-08-0510-29-42TMGPPCH2PG-2P-LINKER-DMHBI_PROFIL.D)</p> <p>mAU</p> <p>600 500 400 300 200 100 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p> <p>DAD1 B, Sig=390.4 Ref=360,100 (PIOTRS\2020-08-0510-29-42TMGPPCH2PG-2P-LINKER-DMHBI_PROFIL.D)</p> <p>mAU</p> <p>400 350 300 250 200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p>




Compound 3a-3': TMGppCH₂pG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	




Compound 3c-2': TMGppCH₂pG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=off (PIOTRS\2021-06-1710-12-59TMGPPCH2PG-2P-LINK-HEMABI.D)</p> <p>DAD1 B, Sig=390,4 Ref=off (PIOTRS\2021-06-1710-12-59TMGPPCH2PG-2P-LINK-HEMABI.D)</p> <p>mAU</p> <p>min</p>




Compound 3c-3': TMGppCH₂pG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2020-08-0418-51-39TMGPPCH2PG-3P-LINKER-HEMABI_PROFIL.D)</p> <p>DAD1 B, Sig=450,4 Ref=360,100 (PIOTRS\2020-08-0418-51-39TMGPPCH2PG-3P-LINKER-HEMABI_PROFIL.D)</p>




Compound 4a-2': TMGpppA-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (PIOTRS\46A000416.D)</p> <p>mAU</p> <p>600 500 400 300 200 100 0</p> <p>0 5 10 15 min</p> <p>13.748</p> <p>DAD1 B, Sig=390.16 Ref=360,100 (PIOTRS\46A000416.D)</p> <p>mAU</p> <p>400 300 200 100 0</p> <p>0 5 10 15 min</p> <p>13.748</p>




Compound 4a-3': TMGpppA-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=540,100 (PIOTRS\2024-05-1313-37-26TMGPPPA-3P-LINK-DMHBI.D)</p> <p>mAU</p> <p>1000</p> <p>800</p> <p>600</p> <p>400</p> <p>200</p> <p>0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p> <p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2024-05-1313-37-26TMGPPPA-3P-LINK-DMHBI.D)</p> <p>mAU</p> <p>800</p> <p>600</p> <p>400</p> <p>200</p> <p>0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p>






Compound 4c-2': TMGpppA-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS46B_PROFIL00016.D)</p> <p>mAU</p> <p>300 250 200 150 100 50 0</p> <p>0 5 10 15 min</p> <p>14.683</p> <p>DAD1 B, Sig=450,16 Ref=360,100 (PIOTRS46B_PROFIL00016.D)</p> <p>mAU</p> <p>400 300 200 100 0</p> <p>0 5 10 15 min</p> <p>14.681</p>







Compound 4c-3': TMGpppA-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	





Compound 5a-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=540,100 (PIOTRS\2022-01-1717-16-14TMGPPPG-2P-LINK-DMHBI.D)</p>  <p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2022-01-1717-16-14TMGPPPG-2P-LINK-DMHBI.D)</p> 



Compound 5a-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	


MS (-) ESI (Calc. [M-H]⁻ C₄₂H₅₃N₁₆O₂₆P₄⁻ : 1321.2273, found : 1321.22689)



Compound 5c-2': TMGpppG-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=540,100 (PIOTRS\2022-01-1710-38-02TMGPPPG-2P-LINK-HEMABI.D)</p> <p>mAU</p> <p>800</p> <p>600</p> <p>400</p> <p>200</p> <p>0</p> <p>0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 min</p> <p>DAD1 C, Sig=450,4 Ref=540,100 (PIOTRS\2022-01-1710-38-02TMGPPPG-2P-LINK-HEMABI.D)</p> <p>mAU</p> <p>1400</p> <p>1200</p> <p>1000</p> <p>800</p> <p>600</p> <p>400</p> <p>200</p> <p>0</p> <p>0 2.5 5 7.5 10 12.5 15 17.5 20 22.5 min</p>

MS (-) ESI (Calc. [M-H]⁻ C₄₃H₅₆N₁₇O₂₄P₄⁻ : 1318.2640, found : 1318.26377)





Compound 5c-3': TMGpppG-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	







Compound 6a: TMGpppA-2'+3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)






Compound 6c: TMGpppA-2'+3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=540,100 (PIOTRS\2021-10-0214-05-4149B_TMGP PPPA-LINK-HEMABI_MIX.D)</p>  <p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2021-10-0214-05-4149B_TMGP PPPA-LINK-HEMABI_MIX.D)</p> 





Compound 7a-2': TMGppp-5'-SG-2'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2020-10-2912-26-51TMGPPPSG-2P-O-LINKER-DMHBI_PROFIL.D)</p> <p>mAU</p> <p>250 200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p> <p>12.977 13.162</p> <p>DAD1 B, Sig=390,4 Ref=360,100 (PIOTRS\2020-10-2912-26-51TMGPPPSG-2P-O-LINKER-DMHBI_PROFIL.D)</p> <p>mAU</p> <p>175 150 125 100 75 50 25 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p> <p>13.622 13.162</p>




Compound 7a-3': TMGppp-5'-SG-3'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-DMHBI (NH₄⁺ salt)









Compound 7b-2': TMGppp-5'-SG-2'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2020-10-2211-40-44TMGPPPSG-2P-O-LINKER-OHBDI_PROFIL.D)</p> <p>DAD1 B, Sig=385,4 Ref=360,100 (PIOTRS\2020-10-2211-40-44TMGPPPSG-2P-O-LINKER-OHBDI_PROFIL.D)</p> <p>mAU</p> <p>350 300 250 200 150 100 50 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p> <p>mAU</p> <p>50 40 30 20 10 0</p> <p>0 2 4 6 8 10 12 14 16 18 min</p>






Compound 7b-3': TMGppp-5'-SG-3'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\2020-10-3010-32-26TMGPPPSG-3P-O-LINKER-OHBDI_PROFIL.D)</p>  <p>DAD1 B, Sig=385,4 Ref=360,100 (PIOTRS\2020-10-3010-32-26TMGPPPSG-3P-O-LINKER-OHBDI_PROFIL.D)</p> 






Compound 8a: TMGpppG-N1-CH₂-triazole-CH₂CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	





Compound 8b: TMGpppG-N1-CH₂-triazole-CH₂CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	





Compound 9a-2': TMG(-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI)pppG (NH₄⁺ salt)









Compound 9a-3': TMG(-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI)pppG (NH₄⁺ salt)






Compound 9b-2': TMG(-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-oHBI)pppG (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=540,100 (PIOTRS\2021-11-0510-12-1470D_TMG(2P-O-LINK-OHBI)PPPG.D)</p>  <p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2021-11-0510-12-1470D_TMG(2P-O-LINK-OHBI)PPPG.D)</p> 





Compound 9b-3': TMG(-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-oHBI)pppG (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	




Compound 10a-2': GMP-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)







Compound 10a-3': GMP-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\11B_PROFIL01765.D)</p> <p>DAD1 B, Sig=386,16 Ref=360,100 (PIOTRS\11B_PROFIL01765.D)</p> <p>min</p> <p>mAU</p> <p>175 150 125 100 75 50 25 0</p> <p>0 2.5 5 7.5 10 12.5 15 17.5</p> <p>min</p> <p>mAU</p> <p>175 150 125 100 75 50 25 0</p> <p>0 2.5 5 7.5 10 12.5 15 17.5</p> <p>min</p>





Compound 10b-2': GMP-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-oHBI (NH₄⁺ salt)







Compound 10b-3': GMP-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-OHBI (NH₄⁺ salt)







Compound 10c-2': GMP-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)








Compound 10c-3': GMP-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)






Compound 10d-2': GMP-2'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-ACVJ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions c)	



Compound 10d-3': GMP-3'-O-C(O)-NH-CH₂-CH₂-triazole-CH₂-ACVJ (NH₄⁺ salt)




MS (-) ESI (Calc. [M-H]⁻ C₃₂H₃₆N₁₂O₁₀P⁻ : 779.2421, found: 779.24286)





Compound 11b-2': GMP-2'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=off (PIOTRS\2021-03-1511-17-13GMP-2P-O-LINKER2-OHBDI.D)</p> <p>DAD1 B, Sig=390,4 Ref=off (PIOTRS\2021-03-1511-17-13GMP-2P-O-LINKER2-OHBDI.D)</p> <p>Both chromatograms show a single prominent peak at 14.761 minutes, indicating the presence of the compound.</p>





Compound 11b-3': GMP-3'-O-C(O)-NH-CH₂-triazole-CH₂CH₂-oHBI (NH₄⁺ salt)






Compound 12a: phosphonate-CH₂-triazole-CH₂-DMHBI (NH₄⁺ salt)







Compound 12b: phosphonate-CH₂-triazole-CH₂-oHBI (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=600,4 (PIOTRS\2021-03-1718-10-34OHBDI-PHOSPHONATE.D)</p> <p>DAD1 B, Sig=380,4 Ref=600,4 (PIOTRS\2021-03-1718-10-34OHBDI-PHOSPHONATE.D)</p>






Compound 12c: phosphonate-CH₂-triazole-CH₂-HEMABI (NH₄⁺ salt)






Compound 12d: phosphonate-CH₂-triazole-CH₂-ACVJ (NH₄⁺ salt)


Chemical structure	
RP-HPLC (conditions b)	<p>DAD1 B, Sig=455,16 Ref=360,100 (PIOTRS\23A-JUL0000094.D)</p> 



Compound 13: Im-GDP-2'+3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)


Chemical structure








Compound 14: Im-GpCH₂p-2'+3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)


Chemical structure








Compound 15: Im-ADP-2'+3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254.4 Ref=360,100 (PIOTRS\PSU000747.D)</p> 





Compound 16: 5'-I-Guo-2'+3'-O-C(O)-NH-C₃H₃


Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\PSU000781.D)</p> 




Compound 17: 5'-S-GMP-2'+3'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 A, Sig=254,4 Ref=360,100 (PIOTRS\PSU01000648.D)</p> 

MS (-) ESI (Calc. [M-H]⁻ C₁₄H₁₆N₆O₈PS : 459.0493, found: 459.05005)





Compound 18: Im-5'-S-GMP-2'+3'-O-C(O)-NH-C₃H₃ (NH₄⁺ salt)



Chemical structure


RP-HPLC (conditions c)








Compound 19: Im-TMGMP-2'+3'-O-C(O)-NH-CH₂CH₂-N₃ (NH₄⁺ salt)


Chemical structure







Compound 20: DMHBI-C₃H₃



Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2022-02-0914-52-27DMHBI-C3H3_PROFIL.D)</p> 











Compound 21: oHBI-C₃H₃


Chemical structure	
RP-HPLC (conditions b)	<p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2022-02-0916-23-49OHBI-C3H3_PROFIL.D)</p> 
















Compound 22: HEMABI-C₃H₃

Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 C, Sig=450,4 Ref=540,100 (PIOTRS\2022-02-0915-53-14HEMABI-C3H3_PROFIL.D)</p>  <p>mAU</p> <p>1750 1500 1250 1000 750 500 250 0</p> <p>0 5 10 15 20 25 min</p> <p>19.511</p> <p>21.956</p>










Compound 23: ACVJ-C₃H₃



Chemical structure	
RP-HPLC (conditions b)	<p>DAD1 C, Sig=450,4 Ref=540,100 (PIOTRS\2024-05-1014-50-14ACVJ-PGYL.D)</p> <p>mAU</p> <p>700 600 500 400 300 200 100 0</p> <p>0 5 10 15 20 25 30 35 38.460 40 45 min</p> <p>Area: 114884</p>










Compound 24: DMHBI-CH₂CH₂-N₃



Chemical structure	
RP-HPLC (conditions c)	<p>DAD1 B, Sig=390,4 Ref=540,100 (PIOTRS\2022-03-3013-07-00DMHBI-AZIDE.D)</p> 










Compound 25: oHBI-CH₂CH₂-N₃












UV-VIS, excitation and emission spectra




TMG_nG-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (1a-3')




TMG-5'-S-**pppG-2'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (2a-2')**




TMG-5'-S-*ppp*G-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (2a-3')




TMGppCH₂pG-2'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (3a-2')




TMGppCH₂pG-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (3a-3')



TMGpppA-2'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (4a-2')




TMGpppA-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (4a-3')




DODAJ


TMG^{red}pppG-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (5a-3')




TMG_npppA-2'+3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (6a)




TMGppp-5'-SG-2'-O-C(O)NH-CH₂-triazole-CH₂CH₂-DMHBI (7a-2')




TMGppp-5'-SG-3'-O-C(O)NH-CH₂-triazole-CH₂CH₂-DMHBI (7a-3')




TMG_npppG-N1-CH₂-triazole-CH₂CH₂-DMHBI (8a)







TMG(-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI)pppG (9a-3')




GMP-2'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (10a-2')




GMP-3'-O-C(O)NH-CH₂CH₂-triazole-CH₂-DMHBI (10a-3')





DMHBI-CH₂-triazole-CH₂-phosphonate (**12a**)








TMGpppG-N1-CH₂-triazole-CH₂CH₂-oHBI (8b**)**
















HEMABI-CH₂-triazole-CH₂-phosphonate (**12c**)





ACVJ-CH₂-triazole-CH₂-phosphonate (**12d**)

